CTT Pharma Registers 6.25M Shares for Resale; Eyes $10M ELOC
CTT Pharmaceutical Holdings filed an S-1 registration statement for the resale of up to 6,250,000 shares of common stock by RH2 Partners, a selling stockholder. While the company will not receive proceeds from this resale, it may receive up to $10,000,000 from the sale of shares to RH2 Partners under an Equity Line of Credit (ELOC) agreement. The company, a development-stage entity specializing in fast-dissolving drug delivery systems, plans to use any ELOC proceeds for working capital, strategic, and general corporate purposes, prioritizing at least $500,000 for in-house manufacturing equipment. CTT Pharma reported losses of $250,229 in 2024 and $155,907 in 2025, and its auditors have issued a "going concern" qualification, highlighting the need for this financing despite potential dilution.
Key Highlights
- Registers up to 6,250,000 common shares for resale by Selling Stockholder RH2 Partners.
- Company may receive up to $10,000,000 from an Equity Line of Credit (ELOC) with RH2 Partners.
- Plans to use at least $500,000 of ELOC proceeds for in-house manufacturing equipment.
- Reported a net loss of $250,229 for the fiscal year ended December 31, 2024.
- Reported a net loss of $155,907 for the fiscal year ended December 31, 2025.
- Common stock trades on OTCQB under "CTTH"; closing price $0.0825 on May 26, 2026.
- Management collectively owns approximately 50% of outstanding common stock.
- US Patents for its delivery system are set to expire between 2036 and 2038.
Price Impact
More from CTTH